Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice

Proceedings of the Nutrition Society

Volumn 75, Issue 1, 2016, Pages 1-9

  Jump, Donald B ^a   Depner, Christopher M ^a   Tripathy, Sasmita ^a   Lytle, Kelli A ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Fibrosis; Inflammation; N 3 PUFA; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

ACYL COENZYME A DESATURASE; ALANINE AMINOTRANSFERASE; CD14 ANTIGEN; CHOLESTEROL; COLLAGEN TYPE 1; CRYOPYRIN; DOCOSAPENTAENOIC ACID; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER 5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; MAX PROTEIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN P50; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SATURATED FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUCROSE; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ANIMAL MODEL; BODY FAT; BODY WEIGHT; CELL DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DYSLIPIDEMIA; ENDOTOXEMIA; FAT INTAKE; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; HEPATITIS; HYPERGLYCEMIA; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; METABOLOMICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PREVALENCE; PROTEIN EXPRESSION; REMISSION; RISK FACTOR; WEIGHT CHANGE; WESTERN DIET;

EID: 84959183349     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S002966511500244X     Document Type: Conference Paper

References (109)

1. Centers for Disease Control (2015) Adult obesity facts. http://www.cdc. gov/obesity/data/adult. html (accessed April 2015).
2. Centers for Disease Control (2015) Childhood obesity facts. http://www.cdc. gov/obesity/data/childhood. html (accessed April 2015).
3. Farrell GC & Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112.
4. Cohen JC, Horton JD & Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332, 1519-1523.
5. Bellentani S, Scaglioni F, Marino M et al. (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28, 155-161.
6. Angulo P & Lindor KD (2002) Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17, Suppl. , S186-S190.
7. Neuschwander-Tetri BA & Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37, 1202-1219.
8. Kim CH & Younossi ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75, 721-728.
9. Alberti KG, Zimmet P & Shaw J (2005) The metabolic syndrome-a new worldwide definition. Lancet 366, 1059-1062.
10. Vernon G, Baranova A & Younossi ZM (2011) Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34, 274-285.
11. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346, 1221-1231.
12. Chalasani N, Younossi Z, Lavine JE et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592-1609.
13. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40, Suppl. 1, S17-S29.
14. PrashanthM, GaneshHK, VimaMVet al. (2009) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 57, 205-210.
15. Soderberg C, Stal P, Askling J et al. (2010) Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595-602.
16. Ekstedt M, Franzen LE, Mathiesen UL et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865-873.
17. Adams LA, Lymp JF, St Sauver J et al. (2005) The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 129, 113-121.
18. McCullough AJ (2004) The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8, 521-533.
19. McCollough AJ (2011) Epidemiology of the metabolic syndrome in the USA. J Dig Dis 12, 333-340.
20. Leslie M (2015) The liver's weight problem. Science 18-20.
21. Day CP & James OF (1998) Steatohepatitis: a tale of two hits? Gastroenterology 114, 842-845.
22. LaBrecque D, Abbas Z, Anania F et al. (2012) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. World Gastroenterol Org Global Guidelines 1-29.
23. Tilg H & Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836-1846.
24. Hashimoto E, Tokushige K & Farrell GC (2011) Histological features of non-alcoholic fatty liver disease: what is important? J Gastroenterol Hepatol 27, 5-7.
25. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669.
26. Abdelmalek MF, Suzuki A, Guy C et al. (2010) Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961-1971.
27. Guturu P & Duchini A (2012) Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol 2012, 212865.
28. Wouters K, van Gorp PJ, Bieghs V et al. (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486.
29. Pagadala M, Kasumov T, McCullough AJ et al. (2012) Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 23, 365-371.
30. Harte AL, da Silva NF, Creely SJ et al. (2010) Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflammation 7, 15. PubMed.
31. Hooper AJ, Adams LA & Burnett JR (2011) Genetic determinants of hepatic steatosis in man. J Lipid Res 52, 593-617.
32. Bieghs V, Van Gorp PJ, Wouters K et al. (2012) LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS ONE 7, e30668.
33. Joyce SA, MacSharry J, Casey PG et al. (2014) Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci USA 111, 7421-7426.
34. Elinav E, Ali M, Bruck R et al. (2009) Competitive in hibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 49, 278-286.
35. Donnelly KL, Smith CI, Schwarzenberg SJ et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351.
36. Matherly SC & Puri P (2012) Mechanisms of simple hepatic steatosis: not so simple after all. Clin Liver Dis 16, 505-524.
37. Toshimitsu K, Matsuura B, Ohkubo I et al. (2007) Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23, 46-52.
38. Musso G, Gambino R, De Michieli F et al. (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909-916.
39. Capanni M, Calella F, Biagini MR et al. (2006) Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23, 1143-1151.
40. Cortez-Pinto H, Jesus L, Barros H et al. (2006) How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 25, 816-823.
41. Levy JR, Clore JN & StevensW (2004) Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 39, 608-616.
42. Pachikian BD, Essaghir A, Demoulin JB et al. . Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLoS ONE 6, e23365.
43. Jump DB, Tripathy S & Depner CM (2013) Fatty acidregulated transcription factors in the liver. Annu Rev Nutr 33, 249-269.
44. Zelber-Sagi S, Ratziu V & Oren R (2011) Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 17, 3377-3389.
45. Tetri LH, Basaranoglu M, Brunt EM et al. (2008) Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295, G987-G995.
46. Lottenberg AM, Afonso Mda S, Lavrador MS et al. (2012) The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem 23, 1027-1040.
47. Wouters K, van Bilsen M, van Gorp PJ et al. (2010) Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 584, 1001-1005.
48. Teratani T, Tomita K, Suzuki T et al. (2012) A highcholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142, 152-164 e10.
49. Depner CM, Torres-Gonzalez M, Tripathy S et al. (2012) Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/-mice. J Nutr 142, 1495-1503.
50. Yasutake K, Nakamuta M, Shima Y et al. (2009) Nutritional investigation of non-obese patients with nonalcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 44, 471-477.
51. Walenbergh SMA, Koek GH, Bieghs V et al. (2013) Non-alcoholic steatohepatitis: the role of oxidized lowdensity lipoproteins. J Hepatol 58, 801-820.
52. Marriott BP, Olsho L, Hadden L et al. (2010) Intake of added sugars in the United States: what is the measure? Am J Clin Nutr 94, 1652-1653.
53. Chun OK, Chung CE, Wang Y et al. (2010) Changes in intakes of total and added sugar and their contribution to energy intake in the U. S. Nutrients 2, 834-854.
54. Chanmugam P, Guthrie JF, Cecilio S et al. (2003) Did fat intake in the United States really decline between 1989-1991 and 1994-1996? J Am Diet Assoc 103, 867-872.
55. Lee S, Harnack L, Jacobs DR Jr et al. (2007) Trends in diet quality for coronary heart disease prevention between 1980-1982 and 2000-2002: the Minnesota Heart Survey. J Am Diet Assoc 107, 213-222.
56. Marriott BP, Olsho L, Hadden L et al. (2010) Intake of added sugars and selected nutrients in the United States, National Health and Nutrition Examination Survey (NHANES) 2003-2006. Crit Rev Food Sci Nutr 50, 228-258.
57. Vos MB, Kimmons JE, Gillespie C et al. (2008) Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 10, 160.
58. Lim JS, Mietus-Snyder M, Valente A et al. (2010) The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7, 251-264.
59. Bizeau ME & Pagliassotti MJ (2005) Hepatic adaptations to sucrose and fructose. Metabolism 54, 1189-1201.
60. Leclercq IA, Field J, Enriquez A et al. (2000) Constitutive and inducible expression of hepatic CYP2E1 in leptindeficient ob/ob mice. Biochem Biophys Res Commun 268, 337-344.
61. Schalkwijk CG, Stehouwer CD & van Hinsbergh VW (2004) Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 20, 369-382.
62. Bunn HF & Higgins PJ (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213, 222-224.
63. Bose T & Chakraborti AS (2008) Fructose-induced structural and functional modifications of hemoglobin: implication for oxidative stress in diabetes mellitus. Biochim Biophys Acta 1780, 800-808.
64. Wei Y, Wang D, Moran G et al. (2013) Fructose-induced stress signaling in the liver involves methylglyoxal. Nutr Meta (Lond) 10, 32-38.
65. Chan HL, de Silva HJ, Leung NW et al. (2007) How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 22, 801-808.
66. Musso G, Cassader M, Rosina F et al. (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD) : a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885-904.
67. Petit JM, Guiu B, Duvillard L et al. (2012) Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes. Clin Nutr 31, 520-525.
68. Zheng JS, Xu A, Huang T et al. (2012) Low docosahexaenoic acid content in plasma phospholipids is associated with increased non-alcoholic fatty liver disease in China. Lipids 47, 549-556.
69. Parker HM, Johnson NA, Burdon CA et al. (2012) Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 56, 944-951.
70. Di Minno MN, Russolillo A, Lupoli R et al. (2012) Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 18, 5839-5847.
71. Nobili V, Bedogni G, Alisi A et al. (2011) Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96, 350-353.
72. Shapiro H, Tehilla M, Attal-Singer J et al. (2011) The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 30, 6-19.
73. Cohen-Naftaly M & Friedman SL (2011) Current status of novel antifibrotic thearpies in patients with chronic liver disease. Ther Adv Gastroenterol 4, 391-417.
74. Schuppan D & Kim YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123, 1887-1901.
75. Wang Y, Botolin D, Christian B et al. (2005) Tissuespecific, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res 46, 706-715.
76. Tripathy S, Torres-Gonzalez M & Jump DB (2010) Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese C57BL/6J mice. J Lipid Res 51, 2642-2654.
77. Depner CM, Philbrick KA & Jump DB (2013) Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr (-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J Nutr 143, 315-323.
78. Depner CM, Traber MG, Bobe G et al. (2013) A metabolomic analysis of omega-3 fatty acid mediated attenuation of western diet-induced non-alcoholic steatohepatitis in LDLR-/-mice. Plos ONE 8, e83756.
79. Tripathy S & Jump DB (2013) Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-Vaccenic acid synthesis in diet-induced obese mice. J Lipid Res 54, 71-84.
80. Tripathy S, Lytle KA, Stevens RD et al. (2014) Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL/6J mice. J Lipid Res 55, 1448-1464.
81. Saraswathi V, Gao L, Morrow JD et al. (2007) Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. J Nutr 137, 1776-1782.
82. Ganz M, Bukong TN, Csak T et al. (2015) Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterolsugar diet model in mice. J Transl Med 13, 193-207.
83. Charlton M, Krishnan A, Viker K et al. (2011) Fast food diet mouse: novel small animal model of NASH with balloning, progressive fibrosis and high physiological facelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301, G825-GG34.
84. Cordain L, Eaton SB, Sebastian A et al. (2005) Orgins and evolution of the western diet: health implications for the 21st century. Am J Clin Nutr 81, 341-354.
85. Ishimoto T, Lanaspa MA, Rivard CJ et al. (2013) High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58, 1632-1643.
86. Arendt BM, Comelli EM, Ma DW et al. (2015) Altered hepatic gene expression in non-alcoholic fatty liver disease is associated with lower n-3 and n-6 polyunsaturated fatty acids. Hepatology 61, 1565-1578.
87. Lee JJ, Lambert JE, Hovhannisyan Y et al. (2015) Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr 101, 34-43.
88. Sofi F, GiangranDi I, Cesari F et al. (2011) Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 61, 792-802.
89. Bulchandani DG, Nachnani JS, Nookala A et al. (2011) Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. Eur J Gastroenterol Hepatol 22, 1245-1252.
90. Ishikawa Y, Yokoyama M, Saito Y et al. (2011) Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J 74, 1451-1457.
91. Kishino T, Ohnishi H, Ohtsuka K et al. (2011) Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury. Clin Chem Lab Med 49, 159-162.
92. Scorletti E, Bhatia L, McCormick KG et al. (2014) Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: results from the WELCOME study. Hepatology 60, 1211-1221.
93. Kadiiska MB, Gladen BC, Baird DD et al. (2005) Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38, 698-710.
94. US National Institute of health (2015) NAFLD, NASH and omega-3 fatty acids. http://www.clinicaltrials. gov. (accessed April 2015).
95. Barter P & Ginsberg HN (2008) Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 102, 1040-1045.
96. Superko HR, Superko SM, Nasir K et al. (2013) Omega-3 fatty acid blood levels. Clinical significance and controversy. Circulation 128, 2154-2161.
97. Lockyer S, Tzanetou M, Carvalho-Wells AL et al. (2012) STAT gene dietary model to implement diets of differing fat composition in prospectively genotyped groups (apoE) using commercially available foods. Br J Nutr 108, 1705-1713.
98. Di Stasi D, Bernasconi R, Marchioli R et al. (2004) Early modification of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 PUFA. Eur J Clin Pharmacol 60, 183-190.
99. Cani PD, Amar J, Iglesias MA et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772.
100. Leclercq IA, Farrell GC, Schriemer R et al. (2002) Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37, 206-213.
101. Marra F, Gastaldelli A, Baroni GS et al. (2008) Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med 14, 72-81.
102. Akira S & Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4, 499-511.
103. Erridge C, Attina T, Spickett CM et al. (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86, 1286-1292.
104. Laugerette F, Vors C, Geloen A et al. (2011) Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutritional Biochem 22, 53-59.
105. Goel A, Gupta M & Aggarwal R (2014) Gut microbiota and liver disease. J Gastroenterol Hepatol 29, 1139-1148.
106. Henao-Mejia J, Elinav E, Jin C et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185.
107. Adinolfi LE & Restivo L (2011) Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol 5, 147-150.
108. Brenner DA, Seki E, Taura K et al. (2011) Non-alcoholic steatohepatitis-induced fibrosis: toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res 41, 683-686.
109. Bi P & Kuang S (2015) Notch signaling as a novel regulator of metabolism. Trends EndocrinolMetabol 26, 248-255.